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Objective: To propose benchmark outcome values in liver transplantation,
serving as reference for assessing individual patients or any other patient
groups.
Background: Best achievable results in liver transplantation, that is, bench-
marks, are unknown. Consequently, outcome comparisons within or across
centers over time remain speculative.
Methods: Out of 7492 liver transplantation performed in 17 international
centers from 3 continents, we identified 2024 low risk adult cases with a
laboratory model for end-stage liver disease score 20 points, a balance of
risk score9, and receiving a primary graft by donation after brain death. We
chose clinically relevant endpoints covering intra- and postoperative course,
with a focus on complications graded by severity including the complication
comprehensive index (CCI1). Respective benchmarks were derived from the
median value in each center, and the 75 percentile was considered the
benchmark cutoff.
Results: Benchmark cases represented 8% to 49% of cases per center. One-
year patient-survival was 91.6% with 3.5% retransplantations. Eighty-two
percent of patients developed at least 1 complication during 1-year follow-up.
Biliary complications occurred in one-fifth of the patients up to 6 months after
surgery. Benchmark cutoffs were4 days for ICU stay,18 days for hospital
stay, 59% for patients with severe complications ( Grade III) and 42.1
for 1-year CCI1. Comparisons with the next higher risk group (model for end
stage liver disease 21–30) disclosed an increase in morbidity but within
benchmark cutoffs for most, but not all indicators, while in patients receiving
a second graft from 1 center (n ¼ 50) outcome values were all outside of
benchmark values.
Conclusions: Despite excellent 1-year survival, morbidity in benchmark
cases remains high with half of patients developing severe complications
during 1-year follow-up. Benchmark cutoffs targeting morbidity parameters
offer a valid tool to assess higher risk groups.
Keywords: benchmark, complication, liver transplantation, morbidity,
outcome
(Ann Surg 2017;xx:xxx–xxx)
M ore than 300.000 liver transplantations (LT) have been per-formed worldwide, since its introduction in clinical practice in
the early 1980s.1–3 With major improvements in surgical techniques,
immunosuppression therapy, and patient selection 1-year patient
survival rates have continuously improved to over 85%.2,4–6 LT is
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currently the standard of care for many patients with end-stage liver
disease and liver tumors; a success that has created a dramatic
imbalance between organ need and availability.7,8 To face the
resultant organ shortage, higher-risk grafts are implanted in sick
recipients, potentially jeopardizing the postoperative course. One of
the main issues in evaluating the results of LT is the lack of reliable
comparison to reference groups.
With this in mind, we embarked on the concept of benchmark-
ing, which is widely known as quality assessment and improvement in
the field of banking or industrial manufacturing. Benchmarking has
been used in medicine as a tool for evaluating single-center outcomes
by risk-adjusted comparisons to national data.9–11 We introduced the
idea of identifying best achievable results by selecting low risk cases in
experienced centers and presented a large multicenter study at the
American Surgical Association annual meeting in 2016, proposing
benchmark values for major hepatectomies. The ideal low risk cases
were those performed in healthy living-donor using a comprehensive
analysis of relevant endpoints.12
To define benchmark values in LT, we targeted high-volume
programs, holding an audited prospective database from areas, where
cadaveric LT is common practice. Low risk cases were defined by
pretransplant characteristics, using the model for end-stage liver
disease (MELD) score, which predicts mortality on the waiting list,
and the balance of risk (BAR) score, which takes into account
recipient and donor factors. Other well-established risk factors were
considered exclusion criteria to define the benchmark cohort.13–16
We selected 13 endpoints – to compute benchmark cutoffs based on
their clinical relevance and reproducibility. These benchmark values
may serve as reference for future studies and help assess worldwide
results and trends in the field of LT.
METHODS
Center Selection and Data Sources
We screened countries on every continent for centers perform-
ing at least 50 cadaveric LT per year during the 5-year study period
(2010–2015) and holding a prospectively collected and audited
database. The highest volume centers in the respective countries
were selected and the final collaborative consortium included 17
centers: 11 from Europe, 5 from North America, and 1 from South
America. No Asian center could be included due to the small number
of available cadaveric grafts.
Study Population and Variables of Interest
Benchmark cases were identified in every center database. To
define ‘‘ideal’’ LT cases, we considered the mortality risk of the patients
on thewaiting list aswell as the donor/recipientmatch, and thus selected
patients based on the MELD score and the BAR score.17,18
The MELD score is a scoring system widely used for prioriti-
zation of patients awaiting LT – based on serum levels of bilirubin
and creatinine, and the international normalized ratio for prothrombin
time – predicting the risk of mortality on the waiting list in patients
with chronic liver diseases.18–20 We selected only patients with a
MELD score20 at the time of transplantation, as patients with higher
figures have been shown to display a increasing mortality risk.20
The BAR score predicts post-LT mortality by including donor
age, recipient MELD score, recipient age, retransplant status, the
need for mechanical ventilation, and cold ischemia time.17 Patients
with a BAR score 9 present an ideal donor–recipient match with
very low mortality risk, and this cutoff was thus included as a
selection criteria for benchmark cases.7,17,21
To further narrow the selection of the ‘‘best cases,’’ we
excluded patients with acute liver failure, patients on mechanical
ventilation at the time of surgery, and patients receiving a graft from
donors after circulatory death (DCD).13,16,22–24 In addition, special
situations and technical difficulties impacting outcomes, such as
recipient portal vein thrombosis, previous major abdominal surgery
(hepato-biliary surgery and extensive colorectal surgery), partial
graft implantation or retransplantation were excluded.14,15,25
In summary, patients with a MELD score 20, a BAR score
9 and receiving a standard LT from a donor after brain death were
selected as benchmark cases.
Comparative Cohorts
To compare outcomes from the benchmark cohort, we identi-
fied 2 higher risk groups. First, we considered a slightly higher risk
group from the same centers and study period using identical
selection criteria except for the next higher MELD score ranging
from 21 to 30 points. Second, to test the applicability of the
established benchmark criteria for the assessment of a single-center
cohort, we selected one of the highest risk groups from one of the
benchmark centers – that is, those receiving a second graft due to
failure of the original graft – over the same study period.
Collected Data, Outcomes, and Follow-up
Local investigators collected center-specific data, using a secure
online data entry management system, including the following recipient
and donor characteristics: age, MELD before LT, underlying liver
disease and comorbidities, cold ischemia time, and a variety of postop-
erative events at 4 specific time points (discharge, 3, 6, and 12 mo).
The primary end-point was morbidity and mortality. To assess
LT morbidity, we selected peri- and postoperative parameters with
proven impact on outcomes and costs, namely duration of surgery,
intraoperative blood transfusion, hospital and intensive care unit
(ICU) stay, as well as post-LT complications.26–28
A systematic and comprehensive classification of all postop-
erative complications was performed using the Clavien–Dindo
grading system. This system ranks complications by severity accord-
ing to their therapeutic consequences.29,30 Briefly, grade I and II
complications are events requiring only bedside procedures or a need
for pharmacologic treatments. Grade III complications require sur-
gical, radiological, or endoscopic treatment. Grade IV complications
are life-threatening complications requiring ICU care, while grade V
complications correspond to death. Patients requiring a retransplan-
tation were graded IVa. To get additional information on morbidity,
we then measured the cumulative morbidity using the comprehensive
complication index (CCI1).31,32 The CCI1 expresses morbidity on a
continuous numeric scale from 0 (no complications) to 100 (death)
by weighing all postoperative complications according to the
Clavien–Dindo classification for their respective severity.31 Since
in LT, complications related to the biliary tract are the most common
complications and responsible for major costs and morbidity, they
were additionally analyzed separately.33,34
Statistical Analysis
Benchmark Metrics
Benchmark cutoffs were determined for 1-year mortality,
retransplantations, and peri- and postoperative morbidity indicators
including length of surgery (skin-to-skin time), intraoperative blood
transfusions, renal replacement therapy after transplantation until
discharge, length of ICU, and hospital stay (from day of transplan-
tation until hospital discharge), patients with mild (grade II) and
severe (grade  III) complications, biliary complications, hepatic
artery thrombosis (HAT) and the CCI1 at discharge, 3 months,
6 months, and at 1 year. Every outcome indicator listed above was
defined in the study protocol to secure standardization in data
collection among all centers. Of note, biliary complications were
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defined as every post-transplant event related to the biliary system
such as leaks, bilioma, strictures or infection, and graded according
to the Clavien–Dindo classification, and subsequently integrated in
the CCI1 formula. The median value for every indicator in each
center was determined and the 75th percentile of all center-specific
median values for a given indicator was considered the benchmark
cutoff, as previously reported.12 Thus, we opted for an equal count of
every center in this study, regardless of differences in caseloads.
We conducted descriptive statistics for various intra- and
postoperative parameters to characterize the patient population.
Survival curves were compared by using the log rank test and linear
regression analysis was performed for correlations. A value of P <
0.05 was considered statistically significant. Statistical analysis was
performed using Stat 10.1 and SPSS, version 19.
RESULTS
Benchmark Cohort
Seventeen centers provided 7492 cases of LT over the 5-year
study period. Approximately one quarter (27%, n ¼ 2024) were
benchmark cases with a large variation among centers (range: 8% to
49%) (Fig. 1).
Characteristics and outcomes in the benchmark cohort:
Patients in the benchmark cohort displayed a median donor and
recipient age of 55 (IQR: 43–67) and 57 (IQR: 50–62) years,
respectively. Median MELD and BAR scores were 12 (IQR: 9–
16) and 4 (IQR: 2–6), respectively. Underlying liver diseases in-
cluded hepatocellular carcinoma (47.4%), hepatitis C (78.5%), alco-
holic cirrhosis (26.5%), and hepatitis B (2%). The median graft
preservation time was short with 7 hours cold storage (IQR: 6–9).
The median duration of LT was 5 hours (IQR: 290–480) with low
transfusion requirements [2U RBC (unit of red blood cell), IQR: 0–
5]. Postoperative renal replacement therapy was performed in 6.6%
of cases. Consistently, median length of ICU and hospital stay were
short with 2 (1–5) and 13 (9–20) days, respectively. Overall 1- and 5-
year patient survival-rates were 91.6% (actual survival) and 78.2%
(actuarial survival), respectively. Post-LT complications, however,
occurred frequently during the 1-year follow-up; the majority of
patients (82%) presented at least 1 complication and 58% developed
more than 1 complication. Overall, two-thirds (68.7%) of the patients
developed mild complications ( grade II), while almost half
(48.9%) experienced a severe complication requiring intervention
( grade III). Biliary complications occurred in 18.8% of the
patients; the majority (57.7%) after hospital discharge. Accordingly,
the overall median post-transplant morbidity index (CCI1) increased
over time from 20.9 at discharge (IQR: 0–34.6) to 26.6 at 3 months
(IQR: 8.7–42.4), 29.6 at 6 months (IQR: 12.2–44.9) and 33.5 at
12 months (IQR: 20.9–49.5). Omitting grade I complications for the
CCI1 calculation did not affect the overall median CCI1 value at the
4 different time points.
Center-specific and Volume Effect on Outcomes
We recorded a significant variability in perioperative morbid-
ity indicators among centers, namely median length of surgery (IQR:
4.9–8.1 h), median ICU (IQR: 1–8 d), and hospital stay (IQR: 6–24
d). The same applied to the CCI1 from discharge (IQR: 0–51.7) to
1 year (IQR: 20.9–62.9). These results, however, did not correlate
with the respective center volume. Interestingly, we noted that
centers performing less benchmark cases; that is, higher proportion
of more difficult cases, had less biliary complications in the bench-
mark cohort (Pearson R ¼ 0.68, P ¼ 0.002, Fig. 2).
Benchmark Values
The benchmark cutoffs, calculated as the 75th percentile of
the medians of each center, served to indicate the best achievable
results for each post-LT parameter (Tables 1 and 2). The benchmark
for 1-year mortality and graft-loss are 9% and 11%, respectively.
FIGURE 1. Distribution of LT benchmark
cases among centers.
FIGURE 2. More biliary complication occur in centers with a
higher proportion of benchmark cases.
Annals of Surgery  Volume XX, Number XX, Month 2017 Benchmarks for Liver Transplantation
 2017 Wolters Kluwer Health, Inc. All rights reserved. www.annalsofsurgery.com | 3
Copyright © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
CE: D.C.; ANNSURG-D-17-01248; Total nos of Pages: 7;
ANNSURG-D-17-01248
Benchmark cutoffs – set for specific perioperative parameters –
are 6 hours surgical time, need for 3 red blood units, and 8%
of patients requiring postoperative renal replacement therapy.
Benchmarks for ICU and hospital stays are 4 and 18 days,
respectively. The cutoff for severe (grade III) complications is
59%, for overall biliary complications 28% and for HAT 4.4%,
while the benchmark values for cumulativemorbidity, expressed by
the CCI1 at discharge, 3, 6, and 12months, are 29.6, 34.5, 37.2, and
42.1, respectively.
Higher MELD Cohort
In a next step, we compared outcomes in the benchmark
cohort with sicker transplant recipients, displaying a MELD
score ranging from 21 to 30 (median MELD 24, IQR: 22–27),
but otherwise same selection criteria (Table 2). In this cohort (n ¼
699), 1-year survival was similar to the benchmark cohort (88.7%
vs 91.6%, P ¼ 0.154). Although morbidity increased, most out-
come endpoints remained inside the benchmark cutoffs. Only
intraoperative transfusion rates (5 U RBC vs 3 U RBC), patients
with renal replacement therapy after LT (13.7% vs3%), grade IV
complications (24% vs 20%) and retransplantations (7.1% vs
4%) were outside the benchmark cutoffs. Cumulative post-LT
morbidity, expressed by the CCI1 at discharge and after 1 year,
remained within the benchmark threshold (29.6 vs29.6, and 39.7
vs 42.1).
Second Graft (Retransplantation) Cohort
To test the applicability of the benchmark thresholds in a
high-risk group, we looked at 50 patients receiving a second
transplantation due to graft failure at 1 center. The median MELD
score in that group was 30 (IQR: 24–36) and the median BAR was
17 (IQR: 11–20). Overall, 28% of retransplantations were per-
formed in the first 2 weeks following primary LT, 34% between
day 15 and the first year, and 38% thereafter. The main etiologies
for a retransplantation were primary nonfunction in 26%, non-
anastomotic biliary stenosis in 20%, hepatitis C recurrence in 16%,
and hepatic artery thrombosis in 10% of cases. Except for the
use of 1 DCD graft, all retransplantations were performed with
whole grafts from donors after brain death (n ¼ 49). We observed
a 30% reduction in 1st-year patient survival, when compared
with the benchmark cutoffs (58% vs  88%), and all outcome
parameters in the re-LT groups were unambiguously inferior to
the benchmark cutoffs (Table 2). For example, ICU- and hospital
stays were twice as high (8 d vs  4 d and 28 d vs 18 d,
respectively), and severe complications ( Grade III) (96% vs
59%) as well as biliary complications (42% vs28%), all largely
exceeded benchmark values.
DISCUSSION
This is the first attempt to quantify best possible outcomes
after LT using an international cohort of well-defined benchmark
cases, representing approximately 1 quarter of overall LTs. This
TABLE 1. Benchmark Cutoffs in Liver Transplantation
Perioperative Course
OP duration 6 hours
Intraoperative blood transfusions 3U RBC
Renal replacement therapy 8%
ICU stay 4 days
Hospital stay 18 days
Morbidity and Mortality Discharge 3 months 6 months 1 year
Any complication 80% 90% 90% 94%
Grade II complication 69% 81% 83% 83%
Grade III complication 42% 54% 58% 59%
Biliary complications 12% 18% 20% 28%
Hepatic artery thrombosis (HAT) 4.1% 4.4% 4.4% 4.4%
CCI1 points 29.6 34.5 37.2 42.1
Graft-loss 4% 6% 9% 11%
Mortality 2% 4% 7% 9%
HAT are commonly divided into two distinct entities based on the time of
occurrence after LT. The benchmark cutoffs for early HAT occurring within the first
30 days and for late HAT occurring thereafter are 4.1% and 1%, respectively.
TABLE 2. First-year Outcomes After Liver Transplantation in Two Higher Risk Groups Compared With First-year Benchmark
Cutoffs
MELD 21–30 (n ¼ 699) Retransplantations (n ¼ 50)y Benchmark Cutoffs (at 12 mo)
OP duration, h (IQR) 6 (5–7.5) 6.1 (5–7.6) 6
Intraoperative blood transfusions, number (IQR) 5 (2–8) 6 (4–10) 3
Hospital stay (d), median (IQR) 16 (10–26) 28 (16–51) 18
ICU stay (d), median (IQR) 4 (2–9) 8 (4–22) 4
Renal replacement therapy, patient number (%) 96 (13.7) 21 (42) 8%
Any complication, patient number (%) 616 (88.1) 50 (100) 94%
Grade II complications, patient number (%) 460 (65.8) 39 (78) 76%
Grade IIIa complications, patient number (%) 188 (26.8) 34 (68) 41%
Grade IIIb complications, patient number (%) 180 (25.8) 20 (40) 28%
Grade IV complications, patient number (%) 173 (24) 35 (70) 20%
Grade II complication, patient number (%) 516 (73.8) 42 (84) 82%
Grade III complication, patient number (%) 406 (58.1) 48 (96) 59%
Biliary complications, patient number (%) 109 (15.5) 21 (42) 28%
Retransplantations, patient number (%) 50 (7.1) 5 (10) 4%
CCI1 discharge, median (IQR) 29.6 (8.7–43) 62.1 (42.2–98.7) 29.6
CCI1 3 mo, median (IQR) 33.5 (20.9–47.5) 72.7 (54.6–100) 34.5
CCI1 6 mo, median (IQR) 36.1 (20.9–51.2) 81 (60–100) 37.2
CCI1 at 1 yr, median (IQR) 39.7 (22.6–55.8) 85.8 (64.2–100) 42.1
1-year mortality, patients (%) 62 (8.8) 18 (36) 9%
Value is outside the benchmark cutoff.
yAll values in the retransplantation cohort are outside the benchmark cutoffs.
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analysis is crucial for conclusive comparisons among different
groups of patients, centers, and over time. We chose a number of
clinically relevant endpoints in this ‘‘ideal’’ LT cohort, disclosing an
excellent 1-year survival, but with high postoperative morbidity,
increasing significantly during the first year after LT. The outcome
analysis of 2 higher LT cohorts illustrated the relevance of the
benchmark values.
LT belongs to one of the most successful therapies developed
over the past half century rescuing many patients with almost certain
short-term death to a close-to-normal quality of life and full function
in the society.7 The success of this complex procedure has emerged –
besides center and team experience – through proper patient and
donor selection, at the cost, however, of significant perioperative
morbidity.35 With an ever-increasing gap between need and organ
supply, many groups have developed novel strategies to augment the
number of available grafts such as living donation, donation after
cardiac arrest, or the use of injured grafts, for example, fatty livers.
This raises the question of how to evaluate these strategies, not only
in terms of patient survival, but also by using more subtle morbidity
endpoints with eventually financial burden. This study provides –
through a careful methodology – baseline values for various outcome
indicators in ‘‘ideal’’ LT patients, a concept called ‘‘benchmarking,’’
and a new tool for comparisons with other LT patient groups or even
competitive procedures.
The selection of benchmark patients was performed by a
stepwise risk stratification. First, we selected patients with a BAR
score 9 points since this threshold has been reported to have an
increasing morbidity and length of hospital stay.17,21 Of note, the
combination of high donor age (>40 yrs), high recipient age (>60
yrs), and prolonged cold ischemia (> 12 h) is in theory within the
BAR 9 threshold. Second, we chose recipients with a MELD score
20, as we have shown inferior results at this cutoff.36 Third, we
excluded established risk factors such as retransplantation, portal
vein thrombosis, acute liver failure, or high-risk donors to narrow the
selection toward the optimal scenarios.13,14,16 We did not consider
additional cardiac, pulmonary, or connective tissue diseases of the
recipient since these characteristics are less frequently captured in a
prospective manner, and may lead to missing values.
We solely selected centers with a sufficient caseload, besides a
well-mixed distribution around the world. We, however, made no
restrictions regarding local strategies for graft preservation, implanta-
tion, and reperfusion techniques to be representative of the ‘‘real world.’’
Our first observation was the variation in the proportion of
benchmark cases among centers, ranging from less than 10% to more
than 40% (Fig. 1). This difference likewise reflects how much risk
centers are willing to take in terms of recipient and donor selection.
One factor influencing this decision is the availability of donors,
ranging from 8 to more than 45 donors per million population among
the 17 participating centers.37,38 Low donation rates force LT centers
to take more risk to serve accumulating very sick patients awaiting a
graft. In support of this argument, we noted that higher donation rates
were associated with a higher amount of benchmark cases (data not
shown). Additionally, some centers in the cohort must deal with more
than two-thirds of so-called ‘‘extended criteria donors,’’ the most
frequent being fatty liver grafts, which obviously are associated with
more risk.39,40 Thus, the methodology used for this study further
validates the selection process identifying the ‘‘benchmark cohort.’’
We confirmed excellent survival rates close to 90% in this low
risk population, as documented in most national and regional regis-
tries, but the study revealed impressively high morbidity rates with
many severe complications occurring all over the 1st year post-LT
follow-up. Comparing these data with the results for benchmark
cases in major hepatectomy, we see a significant higher morbidity
rate in the benchmark LT cases.12 For example, benchmark values
in LT cases are 3 times higher for overall and 5 times higher for
severe complications, compared with benchmark values in major
hepatectomy cases (90% vs 31.2% and 58% vs 9.2%). These
results further underline the need to select fine indicators of morbid-
ity as endpoints for comparative studies, while mortality as endpoint
appears too crude and with poor correlation with costs.12,32,41
The main issue in reporting complications has been the
absence of standardization in definition and severity grading of
postoperative negative events, as well as the lack of a reproducible
and ‘‘easy-to-understand’’ metric system.42,43 The Clavien–Dindo
classification of complications – currently adopted in most areas of
the world – ranks complications by severity based on their respective
treatment.29,30 The subsequent development of the CCI1, integrating
all recorded complications into a single formula providing an index
ranging from 0 (no complication) to 100 (death), is a validated
metric system for comparative studies.32,44–48 Together with other
perioperative patient and cost-related outcome indicators, these
morbidity tools were logically selected for establishing benchmark
cutoffs.43
Another controversial and inconsistently reported issue is the
minimum length of postoperative follow-up to accurately assess
morbidity. We previously identified a minimal follow-up of 3 months
to adequately document morbidity after major liver resection.12 Here
looking at a procedure associated with dramatically higher morbidi-
ty, we could document that the minimal follow-up must cover 1 year,
because major complications, mostly biliary, continued to rise
between 6 and 12 months after transplantation. Also interestingly,
mortality increased from 4% to 7% between 3 and 6 months, and
further increased to 9% at 1 year. In contrast, almost all HAToccurred
before hospital discharge; i.e. within 4 weeks; which appears to be a
serious event, since all cases required a retransplantation (data not
shown). Of note, we cannot exclude from our database that other
clinically silent HAT may occur later after surgery.
We also looked at the impact of center-volume on morbidity
and mortality rates in the benchmark cohort. We observed that
centers with a higher proportion of benchmark cases, that is, perform-
ing mostly low risk cases, had more biliary complications. One
explanation could be that centers performing higher proportion of
complex cases may develop better skills in preventing or correcting
biliary problems.
Validation of the benchmark cohort was performed using 2
comparative cohorts. First, we used a slightly higher risk group
(MELD 21–30) to test the ability of the benchmark analysis to
quantify a minor increase in morbidity. Second, we used a single-
center retransplant cohort to test the applicability of the benchmark
cutoffs to quantify the magnitude of a more consequent increase in
mortality and morbidity. In the first comparative group with slightly
higher MELD scores (21–30), we failed to show any impact on
mortality, but overall morbidity increased in this higher MELD
group, with significantly higher need for intraoperative transfusion,
postoperative renal replacement, and more grade IV complications.
This analysis highlights differences, which have escaped to all
previous reports, supporting a high sensitivity for benchmark thresh-
olds. When considering the second comparative group, one of the
highest risk groups from a single center, patients requiring a 2nd
graft, the increase in morbidity becomes obvious covering all
measured endpoints, and consequently quality of life of the patients,
at least for the first year following surgery. This high morbidity
probably has a massive effect on cost, as postoperative complications
were found to be the most significant factors affecting direct and
indirect costs.39
Another important issue to secure quality in outcome research
is the accuracy in capturing postoperative complications, which
depends on prospective collection of data, optimally by an
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independent observer and regular auditing.49 While our study tar-
geted those objectives, we observed variability in grade I compli-
cations among centers calling for suspicion of missing data. We
therefore tested the impact of omitting grade I events for the CCI1.
As shown in the inaugurating report on the CCI1, the contribution of
grade I complications decrease exponentially with the occurrence of
more severe complication (figure in supplementary material online,
http://links.lww.com/SLA/B317).32 Thus, considering high morbid-
ity in the LT cohort, collecting grade I complications can be omitted
in future studies with minimal consequence on outcome data.
Future possible applications of benchmarks could help to
identify relevant performance metrics, and thus contribute to
improve surgical care, techniques, and training (Table 3). In this
context, contrarily to suggestions that reporting on highly selected
cases may cause risk-averse behavior or threats to innovation due to a
fear of not being able to match results and consequently being
blamed,50,51 we would argue that benchmarking rather offers new
horizons. Benchmarking, as proposed here and in our previous work
on major hepatectomy,12 that is, following a strict methodology,
offers reference values applicable somewhat universally, which is
different from traditional comparisons, even when a heterogeneous
group is risk adjusted. In our view, those comparisons are associated
with 3 significant limitations. First, since no reference value is
available, such studies provide only information related to the
examined groups. Second, the lack of standardization in reporting
weakens generalizability of most studies, which typically fail to
provide convincing information on morbidity, and third understand-
ing of the many risk adjustment methodologies is cumbersome for
many clinicians. The concept of benchmarking, as reference values is
simple, informative and thus likely to be adopted for many proce-
dures. Benchmarking would, however, not replace major compre-
hensive databases like the American College of Surgeons National
Surgical Quality Improvement Program, which best provide detailed
outcome information on specific events on individual patients, who
undergo specific interventions.
In conclusion, this multicentric study proposes 13 benchmark
values, whichmay serve as reference to evaluate LTaround the globe.
Any patient or group of patients, who disclose an outcome fitting
within the benchmark values, should be considered ‘‘optimal’’
results. Deviation from those values must of course be discussed
with caution, and interpreted in the context of additional risk
factors. Important subgroups of patients, for example those receiv-
ing a DCD graft or a second graft, may benefit from new benchmark
studies targeting those specific populations. The next logical
application of the current study may be to test how far is the
outcome of marginal grafts or sicker recipients from benchmark
values. Several of the authors currently select their cases to
be presented at morbidity/mortality conference based on the
benchmark cutoffs. We believe that this new concept of bench-
marking, now also available for major liver resection and oeso-
phagectomy,12,52 may find wide acceptance in daily clinical
practice and for future studies.
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